ACM
PCRX icon

Aster Capital Management’s Pacira BioSciences PCRX Stock Holding History

Aster Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13K Sell
202
-114
-36% -$2.69K ﹤0.01% 721
2026
Q1 		$7.85K Buy
+316
New +$7.02K ﹤0.01% 647
2025
Q3 		– Sell
-212
Closed -$5.07K – 1272
2025
Q2 		$5.07K Buy
+212
New +$5.34K ﹤0.01% 859

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aster Capital Management's PCRX Position: Q2 2026 in Review

Aster Capital Management reduced its Pacira BioSciences (PCRX) stake by 36% in Q2 2026, selling an estimated $2.69K and leaving 202 shares worth $5.13K. The position accounts for ﹤0.01% of the portfolio, ranked #721.

Aster Capital Management first reported a position in PCRX in Q2 2025 and has held it in 3 quarters since. The position peaked at $7.85K in Q1 2026. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Aster Capital Management held 202 shares of Pacira BioSciences worth $5.13K as of Q2 2026.
  • Aster Capital Management sold 114 Pacira BioSciences shares in Q2 2026, an estimated $2.69K.
  • Pacira BioSciences made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #721 holding.
  • Aster Capital Management first reported a position in Pacira BioSciences in Q2 2025 and has held it in 3 quarters since.
  • Aster Capital Management's Pacira BioSciences position peaked at $7.85K in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.